Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UTAA09 in Relapsed/Refractory Autoimmune Diseases
NCT06417398Phase 1Not yet recruiting
- Sponsor
- PersonGen BioTherapeutics
- Start
- May 2024
- Primary completion
- Dec 2024
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
01
Overview
Phase 1, open-label, single-arm trial of UTAA09 in systemic lupus erythematosus (SLE), idiopathic inflammatory myopathy (IIM), systemic sclerosis (SSc) and 4 more, sponsored by PersonGen BioTherapeutics. Primary endpoint: Adverse Events at 3 months. Planned start May 2024; status: not yet recruiting.
02
Drugs
UTAA09
03
Conditions
systemic lupus erythematosus (SLE)idiopathic inflammatory myopathy (IIM)systemic sclerosis (SSc)Sjogren's syndromerheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06417398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06417398.